Merck’s Keytruda Regimen Receives Health Canada’s Approval for Malignant Pleural Mesothelioma (MPM)
Shots:
- Health Canada has approved Keytruda + pemetrexed + Pt-based CT as 1L treatment of unresectable advanced or metastatic MPM based on P-II/III (IND.227/KEYNOTE-483) trial led by CCTG in collaboration with NCIN & IFCT
- Trial assessed the regimen in MPM pts (n=440) who received either Keytruda (200mg, IV) + pemetrexed (500mg/m^2) & Pt-based CT on Day 1 of each 21-day cycle for 6 cycles followed by Keytruda for Q3W or pemetrexed + Pt-based CT for 6 cycles
- Study showed improved OS (mOS: 17.3 vs 16.1mos.), a 21% reduction in death risk & improved PFS (mPFS: 7.1mos. in both arms), with ORR of 52% vs 29%
Ref: Merck | Image: Merck
Related News:- Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
